Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... New England Journal of Medicine 375 (4), 311-322, 2016 | 7757 | 2016 |
Liraglutide and renal outcomes in type 2 diabetes JFE Mann, DD Ørsted, K Brown-Frandsen, SP Marso, NR Poulter, ... New England Journal of Medicine 377 (9), 839-848, 2017 | 1323 | 2017 |
Semaglutide and cardiovascular outcomes in obesity without diabetes AM Lincoff, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, ... New England Journal of Medicine 389 (24), 2221-2232, 2023 | 1075 | 2023 |
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials N Chaturvedi, M Porta, R Klein, T Orchard, J Fuller, HH Parving, R Bilous, ... The Lancet 372 (9647), 1394-1402, 2008 | 551 | 2008 |
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial AK Sjølie, R Klein, M Porta, T Orchard, J Fuller, HH Parving, R Bilous, ... The Lancet 372 (9647), 1385-1393, 2008 | 544 | 2008 |
Metabolik sendrom klavuzu M Arslan, A Atmaca, G Ayvaz, N Başkal, Z Beyhan, E Bolu, S Can, ... Türkiye endokrinoloji ve metabolizma derneği, 211-219, 2009 | 107 | 2009 |
Increased thyroid cancer risk in acromegaly S Dagdelen, N Cinar, T Erbas Pituitary 17, 299-306, 2014 | 97 | 2014 |
Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis S Dagdelen, D Sener, M Bayraktar Advances in Therapy 24, 1314-1320, 2007 | 69 | 2007 |
Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients S Dogan, A Atmaca, S Dagdelen, B Erbas, T Erbas Endocrine 45, 114-121, 2014 | 64 | 2014 |
Follow-up of pregnancy in acromegalic women: different presentations and outcomes A Atmaca, S Dagdelen, T Erbas Experimental and clinical endocrinology & diabetes 114 (03), 135-139, 2006 | 63 | 2006 |
Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa F Giorgino, S Bhana, L Czupryniak, S Dagdelen, GR Galstyan, A Janež, ... diabetes research and clinical practice 172, 108617, 2021 | 54 | 2021 |
Endocrine involvement in systemic amyloidosis D Ozdemir, S Dagdelen, T Erbas Endocrine Practice 16 (6), 1056-1063, 2010 | 54 | 2010 |
Clinical characteristics and outcomes of COVID‐19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia) A Sonmez, I Demirci, C Haymana, I Tasci, S Dagdelen, S Salman, N Ata, ... Journal of diabetes 13 (7), 585-595, 2021 | 51 | 2021 |
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial J Deanfield, S Verma, BM Scirica, SE Kahn, SS Emerson, D Ryan, ... The Lancet 404 (10454), 773-786, 2024 | 45 | 2024 |
Peroxisome proliferator-activated receptor-γ: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis A Kepez, A Oto, S Dagdelen BioDrugs 20, 121-135, 2006 | 45 | 2006 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials M Porta, JW Hainer, SO Jansson, A Malm, R Bilous, N Chaturvedi, ... Diabetologia 54, 1298-1303, 2011 | 40 | 2011 |
Volatile Composition, Antioxidant and Antimicrobial Activities of Herbal Plants Used in the Manufacture of V an Herby (OTLU) Cheese S Dagdelen, T Bilenler, G Durmaz, I Gokbulut, AA Hayaloglu, I Karabulut Journal of Food Processing and Preservation 38 (4), 1716-1725, 2014 | 38 | 2014 |
Cavernous sinus invasion might be a risk factor for apoplexy N Cinar, Y Tekinel, S Dagdelen, H Oruckaptan, F Soylemezoglu, T Erbas Pituitary 16, 483-489, 2013 | 35 | 2013 |
Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly M Dural, G Kabakcı, N Çınar, T Erbaş, U Canpolat, KM Gürses, ... Pituitary 17, 163-170, 2014 | 32 | 2014 |
Use of SGLT2 inhibitors during Ramadan: an expert panel statement M Hassanein, A Bashier, H Randeree, M Abouelmagd, W AlBaker, ... diabetes research and clinical practice 169, 108465, 2020 | 30 | 2020 |